Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter indicates a strong performance in the US equity market, with the S&P 500 rising by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter highlights a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - Exact Sciences Corporation (NASDAQ:EXAS) is noted for its cancer screening and diagnostic products, with a market capitalization of $19.453 billion [2] - The stock of Exact Sciences Corporation closed at $102.43 per share on January 16, 2026, with a one-month return of 0.60% and a remarkable 97.97% increase over the past 52 weeks [2] - The company is recognized for its Cologuard noninvasive colorectal cancer screening and has a pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing [3] - Exact Sciences' stock saw positive contributions during the quarter following Abbott's announcement of a definitive all-cash acquisition agreement valued at approximately $21 billion, which provided a significant premium and drove the stock price higher [3]